|
MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology company headquartered in Martinsried/Munich, Germany. MediGene is the first
German biotech company to have revenues from marketed products. It has various drug candidates in clinical development and possesses innovative platform technologies. MediGene focuses on
clinical research and development of novel drugs against cancer and autoimmune diseases.
With the help of our business development team we have found strong partners to further push on our research and development projects, and to expand the distribution of our marketed drugs.
|
Marketed Drugs
Veregen®
Worldwide partnerships
Veregen®, used in the treatment of external genital warts, is MediGene’s first proprietary clinical development. Veregen® is already
available on the US, German, and Austrian markets. Several marketing partnership agreements have been concluded for other countries in Europe, Asia, and America, and will contribute to
future sales growth. Apart from the existing marketing partnerships, MediGene is planning to close further agreements.
|
Country
|
Partner
|
Market Approval
|
Marketing start
|
| America |
|
|
|
| USA |
Fougera Pharmaceuticals Inc.
(previously Nycomed US, Inc.) |
granted |
February 2009 |
| Canada |
Triton Pharma Inc. |
|
|
Mexico, Central America,
Venezuela, Colombia |
Pierre Fabre Medicament |
|
|
| Europe |
|
|
|
| Germany |
Abbott Arzneimittel
GmbH (previously Solvay) |
granted |
March 2010 |
| Austria |
Abbott Products
GmbH (previously Solvay) |
granted |
June 2010
|
| Switzerland |
Abbott Arzneimittel
GmbH (previously Solvay) |
|
|
| Spain |
Juste S.A.Q.F. |
granted |
|
| Portugal |
Juste S.A.Q.F. |
|
|
| France |
Laboratoires Expanscience |
|
|
| Greece, Cyprus |
Meditrina Pharmaceuticals Ltd. |
|
|
| Romania, Bulgaria |
Meditrina Pharamceuticals Ltd.
(via Solartium Group srl) |
|
|
| Belgium, the Netherlands, Luxembourg |
Will-Pharma |
|
|
Serbia, Bosnia
and Herzegovina, Montenegro, Macedonia,
Croatia, Slovenia,
and Albania |
Pharmanova |
|
|
| Turkey |
EIP Eczacibasi |
|
|
| Asia |
|
|
|
| Israel |
Teva Pharmaceutical
Industries |
|
|
| China |
GC Rise |
|
|
| South Korea |
JS Bio Pharm |
|
|
| Taiwan |
SynCore Biotechnology Co., Ltd |
|
|
Eligard®
Partnership with Astellas Pharma
In January 2004, MediGene closed an agreement with the pharmaceutical company Astellas Pharma (previously Yamanouchi) for the commercialization of Eligard® in Europe.
Astellas Pharma, one of the three top leaders in the European urology field of medicine, became MediGene's sales partner for its first drug. Mid of 2010, MediGene sold the full European
marketing and distribution rights to Eligard® to Astellas Pharma Europe Ltd. MediGene still participates in future revenue growth of this drug.
In case you have any questions regarding marketing partnerships for our marketed products, please contact
Ms. Michaela Fabry, Commercial Operations:
email: commercial.operations@medigene.com
phone: +49-89-8565-2956
|
Drug Candidates
Partnerships for our technologies and drug candidates
EndoTAG®-1
EndoTAG®-1 is a novel composition of paclitaxel combined with neutral and cationic lipids. EndoTAG®-1 is designed to suppress tumor growth by
targeting activated endothelial cells, which are required for the formation of new blood vessels in tumors. MediGene has successfully completed two phase II clinical trials of
EndoTAG®-1 in pancreatic cancer and triple-negative breast cancer, and has recently developed a more cost-effective production process. EndoTAG®-1 has orphan
drug status in Europe and the USA, which provides benefits in terms of development, the approval process, and, under certain circumstances, the commercialization of drugs.
MediGene is currently searching for partners in order to conduct the phase III clinical trial in pancreatic cancer of this promising candidate.
RhuDex®
RhuDex® is being developed by MediGene as an agent to treat autoimmune diseases such as rheumatoid arthritis. It is an orally available CD80 antagonist that blocks T-cell
activation and thus has both an immunosuppressive and anti-inflammatory effect. Several phase I as well as a phase Ila pilot trial of this drug candidate were already conducted.
MediGene intends to outlicense this immunological drug candidate once proof of concept has been established, if not earlier.
AAVLP vaccine technology
The AAVLP platform developed by MediGene is an innovative technology platform for the development of prophylactic vaccines that can protect the body against new infections. It is based on
adeno-associated virus-like particles (AAVLP), which serve as a basic structure for the development of new vaccines. MediGene is currently conducting research into the use of AAVLP
technology to treat infections and various types of cancer, as well as the use of AAV libraries for the systematic identification of suitable vaccine candidates. To advance this technology,
MediGene has closed a development collaboration agreement with The Johns Hopkins University in Baltimore, USA.
Based on the data of further preclinical studies, MediGene will decide on the further development or strategic options for the AAVLP project.
Cooperation with scientific institutions
In order to support the development of our research projects, we built up an international scientific network through partnerships. Academic and clinical contacts and
cooperations have been established with leading hospitals and institutions in Europe and in North America.
In case of any questions regarding licensing, please contact Dr. Sandra von Meier, Business Development.
email: business.development@medigene.com
phone: +49-89-8565-2956
|
